Recordati is an international pharmaceutical group dedicated to the research, development, manufacturing and marketing of pharmaceuticals for primary and specialty care as well as orphan drugs for the treatment of rare diseases.
Headquartered in Milan, the Group has a staff of more than 4,100 and has operations in the main European countries, in Central and Eastern Europe, Turkey, North Africa, the United State of America, Canada, Mexico and in some South American countries, Japan and Australia.
Recordati has been listed on the Italian Stock Exchange since 1984.
Recordati offers a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized segment dedicated to treatments for rare diseases.
An efficient field force of medical representatives promotes these products in all countries where subsidiaries have been established.
The company’s leading products are drugs for the treatment of hypertension and other cardiovascular disorders as well as treatments for disorders of the lower urinary tract such as benign prostatic hyperplasia. Drugs for rare diseases are mainly treatments for metabolic deficiencies of a genetic nature.
Recordati sells its proprietary pharmaceuticals directly to the market in the countries where it is present and through licensees elsewhere.
Pharmaceutical production is based mainly in Italy (Milan), France (Montluçon), Turkey (Çerkezköy), in Spain (Zaragoza) and in Tunisia (Ariana). Plants for the production of proprietary active ingredients are situated in Italy (Campoverde di Aprilia, Latina) and in Cork (Ireland).
Research and development activities include projects for the treatment of rare diseases.
Recordati also has a minor pharmaceutical chemicals business. Recordati produces active ingredients for both its own proprietary pharmaceuticals and for the generic drugs industry. Over 90% of third party production is for the export markets.
Key consolidated data
Consolidated revenue for 2018 is € 1,352.2 million
Operating income for 2018 is € 442.2 million
Net income for 2018 is € 312.4 million
Expand through organic development and through acquisitions.
Reinforce presence in existing key markets.
Develop product portfolio by enhancing product pipeline and new product acquisitions.
Develop the business dedicated to treatment of rare diseases on a worldwide basis.